Omicron, the 2-year-old variant, continues to impact us

In November 2021, the world was surprised by the emergence of a highly mutated variant of the coronavirus known as Omicron. This variant quickly became dominant and challenged many assumptions virologists had about the virus. Omicron proved to be staggeringly infectious and was able to evade immunity more effectively than previous variants. It gave rise to numerous descendants that were adept at finding new victims.

Despite the high infectivity of Omicron, it was observed that a smaller fraction of infected people were being hospitalized compared to previous variants. This was likely due to the fact that many individuals had developed immunity to earlier forms of the virus, including both antibodies and immune cells that can recognize and kill infected cells. However, the sheer number of infections caused by Omicron still resulted in a devastating wave of hospitalizations.

Efforts were made to keep up with Omicron's rapid evolution through the development of booster shots targeting specific variants. However, the virus continued to evolve, and a variety of new and more evasive variants emerged. The situation became chaotic, and experts are now closely monitoring the evolving landscape.

One such variant, BA.2.86, initially did not spread rapidly but has recently gained a mutation that allows it to evade even more antibodies. This mutated form, known as JN.1, is currently spreading in France and may soon reach other countries.

While it is difficult to predict the future path of new variants like JN.1, the worldwide immunity that has been developed through natural infection and vaccination means that a smaller fraction of people will die from the virus compared to the beginning of the pandemic. However, the toll of Omicron remains heavy, with more than 80,000 people dying of Covid between October 2022 and September 2023 in the United States alone.

Vaccinations are still seen as beneficial in reducing the severity of infections and saving lives. Annual vaccination campaigns that keep up with the evolving virus could potentially save up to 49,000 lives a year. However, there are concerns that the development of updated vaccines may slow down if governments reduce funding for genetic sequencing of new variants.

In conclusion, two years after its emergence, Omicron continues to evolve and pose challenges. While there have been advancements in understanding and combating the virus, vigilance and continued research are necessary to stay ahead of its mutations and ensure effective control measures.


More from Press Rundown